Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verona Pharma Plc (DE:I9SA)
FRANKFURT:I9SA
Verona Pharma (I9SA) Stock Price & Analysis
2 Followers
I9SA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€10.90 - €20.40
Previous Close€12.9
Volume50.00
Average Volume (3M)106.00
Market Cap
€1.04B
Enterprise Value€833.50M
Total Cash (Recent Filing)$271.77M
Total Debt (Recent Filing)$51.33M
Price to Earnings (P/E)N/A
Beta0.83
Next Earnings
Aug 06, 2024EPS Estimate
-€0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding81,081,772
10 Day Avg. Volume3
30 Day Avg. Volume106
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)3.27
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-10.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-16.36
Forecast
1Y Price Target
€31.52Price Target Upside144.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Verona Pharma News
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
18.00% Other Institutional Investors
82.00% Public Companies and
Individual Investors
I9SA FAQ
What was Verona Pharma Plc’s price range in the past 12 months?
Verona Pharma Plc lowest stock price was €10.90 and its highest was €20.40 in the past 12 months.
What is Verona Pharma Plc’s market cap?
Currently, no data Available
When is Verona Pharma Plc’s upcoming earnings report date?
Verona Pharma Plc’s upcoming earnings report date is Aug 06, 2024 which is in 83 days.
How were Verona Pharma Plc’s earnings last quarter?
Verona Pharma Plc released its earnings results on May 09, 2024. The company reported -€0.037 earnings per share for the quarter, missing the consensus estimate of -€0.028 by -€0.009.
Is Verona Pharma Plc overvalued?
According to Wall Street analysts Verona Pharma Plc’s price is currently Undervalued.
Does Verona Pharma Plc pay dividends?
Verona Pharma Plc does not currently pay dividends.
What is Verona Pharma Plc’s EPS estimate?
Verona Pharma Plc’s EPS estimate is -€0.07.
How many shares outstanding does Verona Pharma Plc have?
Currently, no data Available
What happened to Verona Pharma Plc’s price movement after its last earnings report?
Verona Pharma Plc reported an EPS of -€0.037 in its last earnings report, missing expectations of -€0.028. Following the earnings report the stock price went up 2.206%.
Which hedge fund is a major shareholder of Verona Pharma Plc?
Among the largest hedge funds holding Verona Pharma Plc’s share is RA Capital Management. It holds Verona Pharma Plc’s shares valued at 126M.
---
Verona Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€31.52 (144.33% Upside)
€31.52 (144.33% Upside)
Blogger Sentiment
Bullish
DE:I9SA Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.46%
12-Months-Change
Fundamentals
Return on Equity
-25.30%
Trailing 12-Months
Asset Growth
-10.28%
Trailing 12-Months
Company Description
Verona Pharma Plc
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
---
I9SA Earnings Call
Q1 2024
0:00 / 0:00
---
I9SA Stock 12 Month Forecast
Average Price Target
€31.52
▲(144.33% Upside)
Technical Analysis
Best Analysts Covering I9SA
1 Year
1 Year Success Rate
6/13 ratings generated profit
1 Year Average Return
+98.37%
reiterated a buy rating 5 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +98.37% per trade.
---